97 related articles for article (PubMed ID: 37402749)
1. Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.
Kim JH; Pandit N; Yoo M; Park TH; Choi JU; Park CH; Jung KY; Lee BI
Sci Rep; 2023 Jul; 13(1):10805. PubMed ID: 37402749
[TBL] [Abstract][Full Text] [Related]
2. High resolution crystal structure of BRD4-BD1 in complex with a novel inhibitor precursor.
Ma X; Wang M; Wang F; Li J; Zhang Z; Zhu J; Liu B
Biochem Biophys Res Commun; 2024 Jan; 690():149284. PubMed ID: 38006801
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
[TBL] [Abstract][Full Text] [Related]
4. Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors.
Qiao XP; Wang XT; Wang S; Mu HX; Wang QS; Chen SW
Bioorg Med Chem; 2024 May; 106():117752. PubMed ID: 38749341
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
[TBL] [Abstract][Full Text] [Related]
6. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
[TBL] [Abstract][Full Text] [Related]
7. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation.
Barman S; Sahoo SS; Padhan J; Sudhamalla B
J Biomol Struct Dyn; 2023 Dec; 41(20):10569-10581. PubMed ID: 36524430
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations.
Tong JB; Xiao XC; Luo D; Xu HY; Xing YC; Gao P; Liu Y
Mol Divers; 2024 Apr; 28(2):671-692. PubMed ID: 36773087
[TBL] [Abstract][Full Text] [Related]
10. Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations.
Shi M; Zheng X; Zhou Y; Yin Y; Lu Z; Zou Z; Hu Y; Liang Y; Chen T; Yang Y; Jing M; Lei D; Yang P; Li X
ACS Omega; 2023 Sep; 8(37):33658-33674. PubMed ID: 37744850
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain inhibitors and therapeutic applications.
Gajjela BK; Zhou MM
Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
[TBL] [Abstract][Full Text] [Related]
12. Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection.
Vann KR; Acharya A; Jang SM; Lachance C; Zandian M; Holt TA; Smith AL; Pandey K; Durden DL; El-Gamal D; Côté J; Byrareddy SN; Kutateladze TG
Structure; 2022 Sep; 30(9):1224-1232.e5. PubMed ID: 35716662
[TBL] [Abstract][Full Text] [Related]
13. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.
Qian H; Zhu M; Tan X; Zhang Y; Liu X; Yang L
Cell Death Discov; 2023 Dec; 9(1):470. PubMed ID: 38135679
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors.
Dong R; Zhang C; Wang C; Zhou X; Li W; Zhang JY; Wang M; Xu Y; Sun LP
Bioorg Med Chem; 2022 Feb; 55():116592. PubMed ID: 34999525
[TBL] [Abstract][Full Text] [Related]
15. Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules.
Urick AK; Hawk LM; Cassel MK; Mishra NK; Liu S; Adhikari N; Zhang W; dos Santos CO; Hall JL; Pomerantz WC
ACS Chem Biol; 2015 Oct; 10(10):2246-56. PubMed ID: 26158404
[TBL] [Abstract][Full Text] [Related]
16. Sanguinarine targets BRD4 to suppress cell proliferation and migration in clear cell renal cell carcinoma.
Wen Y; Song Y; Ma Y; Wen J; Yang J
J Biochem Mol Toxicol; 2023 Nov; 37(11):e23451. PubMed ID: 37393519
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation.
Liu Z; Tian B; Chen H; Wang P; Brasier AR; Zhou J
Eur J Med Chem; 2018 May; 151():450-461. PubMed ID: 29649741
[TBL] [Abstract][Full Text] [Related]
18. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
Filippakopoulos P; Picaud S; Fedorov O; Keller M; Wrobel M; Morgenstern O; Bracher F; Knapp S
Bioorg Med Chem; 2012 Mar; 20(6):1878-86. PubMed ID: 22137933
[TBL] [Abstract][Full Text] [Related]
19. From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors.
Koravovic M; Mayasundari A; Tasic G; Keramatnia F; Stachowski TR; Cui H; Chai SC; Jonchere B; Yang L; Li Y; Fu X; Hiltenbrand R; Paul L; Mishra V; Klco JM; Roussel MF; Pomerantz WC; Fischer M; Rankovic Z; Savic V
Eur J Med Chem; 2023 May; 251():115246. PubMed ID: 36898329
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Inhibitors of BRD4 for Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design.
Zhong H; Wang X; Chen S; Wang Z; Wang H; Xu L; Hou T; Yao X; Li D; Pan P
J Med Chem; 2024 Jan; 67(1):138-151. PubMed ID: 38153295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
